id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-5845	Cammarata, Edoardo; Airoldi, Chiara; Colombo, Jacopo; Ucciero, Andrealuna; Mastorino, Luca; Arese, Veronica; Burzi, Lorenza; Castelli, Franco; Chiarpenello, Massimo; Graziola, Francesca; Leporati, Claudia; Ortoncelli, Michela; Paolo, Pella; Pertusi, Ginevra; Pisterna, Alessia; Quaglino, Pietro; Ribero, Simone; Rossotto, Gianluca; Tiberio, Rossana ; Dapavo, Paolo; Savoia, Paola	Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits	2025	8	.pdf	application/pdf	5041	313	55	Two-year follow-up of a dose reduc- tion strategy trial of biologics adalimumab, etanercept, and usteki- numab in psoriasis patients in daily practice. Previous research has demon- strated the effectiveness and safety of a reduced dose com- pared to the standard dose (StD) in psoriasis treatment, with a slightly increased Psoriasis Area and Severity Index (PASI) while maintaining a stable Dermatology Life and Quality In- dex (DLQI)	cache/dpc-5845.pdf	txt/dpc-5845.txt